Trypanosoma brucei comprise the causative agents of sleeping sickness, T. b. gambiense and T. b. rhodesiense, as well as the livestock-pathogenic T. b. brucei. The parasites are transmitted by the tsetse fly and occur exclusively in sub-Saharan Africa. T. brucei are not only lethal pathogens but have also become model organisms for molecular parasitology. We focus here on membrane transport proteins of T. brucei, their contribution to homeostasis and metabolism in the context of a parasitic lifestyle, and their pharmacological role as potential drug targets or routes of drug entry. Transporters and channels in the plasma membrane are attractive drug targets as they are accessible from the outside. Alternatively, they can be exploited to selectively deliver harmful substances into the trypanosome's interior. Both approaches require the targeted transporter to be essential: in the first case to kill the trypanosome, in the second case to prevent drug resistance due to loss of the transporter. By combining functional and phylogenetic analyses, we were mining the T. brucei predicted proteome for transporters of pharmacological significance. Here, we review recent progress in the identification of transporters of lipid precursors, amino acid permeases and ion channels in T. brucei.
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Trypanosoma brucei are neglected pathogens and model parasites
Trypanosoma brucei comprise three subspecies: the livestock-pathogenic T. b. brucei and the humanpathogenic T. b. rhodesiense and T. b. gambiense, the causative agents of East and West African sleeping sickness, respectively. The distribution of the trypanosomes follows that of their vectors, the bloodsucking tsetse flies (Glossina spp.) [1] . Restricted by the Sahara in the north and the Kalahari in the south, the so-called tsetse belt encompasses 36 countries of tropical Africa [1] . Successful programs for the control of tsetse flies and treatment of patients have reduced the prevalence of sleeping sickness, also known as human African trypanosomiasis (HAT), to fewer than 10 000 reported cases per year [2, 3] . To date, the vast majority of cases are due to T. b. gambiense occurring in the Democratic Republic of Congo and the Central African Republic [4] . HAT is a rural disease, affecting the poorest of the poor and always threatening to reemerge should the control be neglected [5] .
African trypanosomes, unlike most other parasitic protozoa, proliferate extracellularly in the blood of the mammalian host [6] . They evade the host's immune response by means of their variant surface glycoprotein (VSG) coat. The dense packing of the VSG dimers, the fast and steady turnover, and the periodic switching of VSG gene expression enable the trypanosomes to elude innate as well as adaptive immune responses [7, 8] . This in turn allows them to dwell in the rich and homeostatic environment of the blood. Once the trypanosomes penetrate the blood-brain barrier and invade the cerebrospinal fluid, the consequences for the host are fatal [1] . With vaccination precluded by antigenic variation, chemotherapy is the only means to control trypanosome infections. Five molecules are presently registered for use in humans: suramin and pentamidine for the first, hemolymphatic stage of the disease; melarsoprol, and the combination of eflornithine and nifurtimox for the second stage with central nervous system involvement [3] . Two promising drug candidates are in clinical development: the nitroimidazole fexinidazole and the benzoxaborole SCYX-7158 [9] .
In the laboratory, T. b. brucei has become a favorite model organism for molecular parasitology for a number of reasons. The trypanosomes can be axenically propagated and cloned in vitro [10, 11] [24] and is accessible via a user-friendly interface at http://tritrypdb.org [25] . The systematic localization of all nonredundant T. brucei proteins at subcellular level is currently in progress and accessible at http:// tryptag.org [26] . Finally, as unicellular and strictly extracellular parasites, the trypanosomes possess a simple topology and are well suited to study transporters of the plasma membrane or intracellular membranes (Fig. 1 ).
Transporters are potential drug targets
All parasites scavenge nutrients from their hosts; this is the very point of parasitism. Therefore, nutrient transporters are at the heart of parasite physiology. Knowledge of a parasite's transport activities (i.e. the transportome) will not only illuminate its metabolic adaptations to parasitism, it will also disclose vulnerable points for chemotherapeutic attack. Nutrient and ion transporters are potential drug targets. Many natural toxins interfere with membrane transporters, for example, the ion channel blockers in the venom of snakes and scorpions [27] . Inhibition of plasma membrane transporters is an attractive chemotherapeutic concept because the inhibitors that act from the outside do not need to be taken up by the target cell. If transporters are of pharmacological interest in general, they are even more so in parasites. Frequently, parasites have lost anabolic pathways and rely on exogenous supply of the respective end products. Thus, parasite evolution is likely to enhance the dependence of cellular metabolism on transporters. This is illustrated by the fact that none of the obligate parasitic protozoa synthesize purines de novo; they all depend on purine import from their hosts to build nucleic acids [28] . The addition of hypoxanthine as a purine source to the medium was key to the development of axenic in vitro culture systems for bloodstream-form T. brucei [11] . T. brucei is predicted to be auxotrophic for the amino acids tryptophan, phenylalanine, tyrosine, glycine, lysine, arginine, histidine, leucine, valine and isoleucine [29] . In addition, the amino acid cysteine was found to be essential for the cultivation of T. brucei. Cysteine is of particular importance as it is key for trypanothione synthesis and therefore cellular redox balance and oxidative stress resistance [30] . Because cysteine can only be taken up in its reduced form, T. brucei cannot be propagated in vitro without addition of a reducing agent to the medium [11] .
Quantitatively, glucose is the most important nutrient, which bloodstream-form T. brucei have to consume in large amounts [31, 32] . However, they only gain two molecules of ATP from one molecule of glucose since they lack a functional Krebs cycle [33] (originally reported by [34] , reviewed in [35] ). The glucose concentration in standard cultivation medium is 10.8 mM [11] , and the trypanosomes' glucose turnover was estimated to correspond to their dry body weight every hour [36, 37] . The main glucose transporter of T. brucei bloodstream forms is the trypanosome hexose transporter THT1 [20, 21] . Halogenated glucose analogs were shown to inhibit THT1 and to be toxic to T. brucei bloodstream forms at low micromolar concentrations [38] .
However, the fact that a particular nutrient is essential for the proliferation of trypanosomes does not necessarily mean that the respective transporter is essential as well. Deletion of genes encoding different purine nucleoside or nucleobase transporters did not result in apparent growth defects in T. brucei bloodstream forms [39, 40] , indicating redundancy in the transportome. Indeed, the genome of T. brucei contains a dozen different purine transporter genes, whose products have overlapping substrate specificities (reviewed in [41] ). Transporters other than those for hexoses or purines have been less extensively studied. Choline, for instance, is imported by both bloodstream and procyclic forms, but the underlying transporter has not yet been identified [42] .
In addition to nutrient uptake, transporters of T. brucei are also involved in signaling. When trypanosomes of the mammalian bloodstream are ingested by a tsetse fly, only the nonproliferative stumpy forms can survive and transform into proliferating procyclic forms [6] . This differentiation can be triggered in vitro by the addition of millimolar concentrations of citrate or cis-aconitate to the culture medium, in combination with a shift from 37°C to lower temperature [43] . Carboxylate transporters of the major facilitator superfamily were shown to be responsible for the uptake of citrate and cis-aconitate. The transporters were termed PAD, proteins associated with differentiation, as RNAi-mediated depletion of PAD led to decreased numbers of cells undergoing differentiation [44] . Interestingly, PAD1 is only expressed in the stumpy forms, which renders it a marker to study the dynamics of stumpy formation [45, 46] or to screen for stumpy-inducing compounds [47] .
Finally, also the transporters that export metabolic end products from the cytosol can be vulnerable points and serve as drug targets. T. brucei bloodstream forms completely rely on glycolysis to make ATP, fermenting glucose in the glycosomes [48] . Pyruvate as an endproduct is secreted into the blood [49] . Paradoxically, the addition of 1 mM pyruvate to the cultivation medium turned out to be key for long-term axenic in vitro culture of T. brucei [11] . Although the pyruvate export route had been well known and characterized [50] [51] [52] 
Transporters can be exploited for drug delivery
Differences in nutrient transporters between host and parasite may be exploited for the specific delivery of antimetabolites to the latter via routes that are absent in the former. The significance of drug uptake for drug susceptibility has been recognized by Paul Ehrlich more than a hundred years ago [57] . However, the pharmacological importance of transporters has long been underestimated because diffusion was thought to be the sole route of uptake of hydrophobic drugs. Functional genomics with the yeast S. cerevisiae has demonstrated that null mutations in transporters frequently cause drug resistance, even to hydrophobic drugs, indicating a major contribution of transporters to cellular drug uptake [58] . In T. brucei, several studies on laboratory-selected mutants have identified lossof-function mutations in nutrient transporters as the underlying mechanisms of drug resistance [19, 39, [59] [60] [61] [62] [63] . These classical genetic approaches have been confirmed and broadened by reverse genetic screens using RNAi libraries for inducible down-regulation of gene expression [13, 14, 64] .
The transporters of T. brucei that have been found to be involved in drug uptake and resistance are summarized in Table 1 . In most cases, the trypanocides that are transported resemble the transporter's natural substrates: the physiological substrates of the aminopurine permease AT1 are adenine and adenosine, its trypanocidal substrates are adenosine analogs and other amidine-containing drugs such as diamidines or melamine-based arsenicals [40, 59, 65, 66] . Similarly, the amino acid permease AAT6, whose physiological substrates are neutral amino acids [67] , also imports the trypanocidal amino acid derivative eflornithine (difluoromethylornithine) [13, 14, 61] . The aquaglyceroporin AQP2 is a more intriguing case. Expressed in X. laevis oocytes, it was shown to transport water, glycerol and ammonia [68, 69] , yet genetic disruption of the gene in T. brucei resulted in resistance to two trypanocides, pentamidine and melarsoprol [70] . Furthermore, mutations in the gene AQP2 were described in melarsoprol-resistant T. b. gambiense field isolates, and expression of wild-type AQP2 in these isolates restored drug susceptibility [71, 72] . Expression of T. brucei AQP2 in promastigote forms of Leishmania mexicana rendered the transformants hypersensitive to pentamidine and cymelarsan [63] . While these functional data clearly indicate a role for AQP2 in drug uptake, there is no similarity between the canonical substrates of aquaglyceroporins and drugs like pentamidine or melarsoprol. Translocation of such molecules through an aquaporin is unprecedented and hard to conceive given the determined crystal structures [73] . Whether the trypanocides are actual substrates of AQP2, or whether they simply bind to AQP2 from the outside and then get internalized by endocytosis, remains controversial [73] . Interestingly, T. brucei isolates lacking a functional AQP2 gene were hypersensitive to SHAM and, in contrast to the situation with wild-type T. brucei, the addition of glycerol did not further exacerbate the effect of SHAM [56] . This indicates that AQP2 mutant trypanosomes, while gaining resistance to melarsoprol and pentamidine, lose the ability to export the physiological substrate glycerol and thus become hypersensitive to inhibitors of the alternative oxidase TAO (see above).
The purine permease AT1 provides proof-of-principle for the strategy to exploit nutrient transporters for antiparasitic drug delivery [74] . Compared to mammalian nucleoside transporters, AT1 has an unusually narrow substrate specificity: of all physiological purine bases and nucleosides it only transports adenosine and adenine [59, 66] . This indicates that an amidine motif is necessary for transport. Indeed, genetic deletion of AT1 in T. brucei conferred resistance not only to adenosine analogs such as cordycepin or tubercidin but also to the diamidines pentamidine and diminazene, and to melaminophenyl arsenicals such as melarsoprol [39, 40] . Expression of AT1 in S. cerevisiae sensitized the yeast cells to these agents [75, 76] . Mapping of the substrate recognition motif of AT1 [66, 74] allowed to design trypanosome-selective molecules using 3-aminooxypropanamine (APA) as a starting point. APA inhibits purified ornithine decarboxylase from T. brucei at nanomolar concentrations, but is inactive against trypanosomes in whole-cell assays [77] . Linking of a melamine moiety to APA produced molecules that exhibited in vitro activity against T. brucei and that were imported via AT1 as indicated by lower activity against at1 null mutant trypanosomes [77] .
Redundancy in the transportome protects trypanosomes
Both scenarios described above, that is, transporters as drug targets or as drug delivery systems, require the targeted transporters to be essential: to kill the parasite or to prevent drug resistance due to loss-of-function mutations. However, only few transporters have so far been identified as being essential for T. brucei bloodstream forms, and most of these localized to the mitochondrial membrane and not to the plasma membrane. An RNAi-mediated high-throughput phenotyping survey that targeted a total of 7435 proteincoding genes of T. brucei revealed 1187 genes (16%) to be essential for the proliferation of bloodstreamform trypanosomes in culture [78] . Only nine of these were annotated to encode transporters (Table 2) , indicating that most of the T. brucei transporter genes are dispensable for growth in standard medium. However, the results of the RNAi screen need to be interpreted with caution, as it did not detect genes that we have validated to be essential for T. brucei bloodstream forms (AAT5, AAT16, TbK1, TbK2, TbHMIT; see below).
Redundancy may emerge by tandem duplication of genes (Fig. 2 ) resulting in transporters with identical or slightly different biochemical properties with the latter being less sensitive to drugs, thereby enabling mutations in drug uptake systems and thus drug resistance. Jackson reported multiple loci for amino acid transporters ranging from 2 to 11 gene copies [79] . It remains to be shown to which degree highly homologous transporters differ in substrate recognition and thus selective drug transport, or display different drug sensitivity. Nonselective down-regulation of all products of the AAT5 (five genes; Fig. 2 ) and AAT16 (two genes) loci by RNAi revealed that arginine and lysine uptake, respectively, is essential for growth of T. brucei [80] . Whether potential drugs are similarly recognized or transported by all members of the AAT5 or AAT16 families is currently unclear, but at least some redundancy may be expected. The recent identification of two high-affinity ornithine transporters in T. brucei showed that although both contribute to intracellular ornithine levels and thus affect sensitivity to anti-HAT drugs, they differ slightly in substrate selectivity [81] . Redundancy may also occur at the substrate level, having more than one distantly related transporter recognizing the same substrate(s). An example for the latter is the neutral amino acid transporter AAT6, which was identified as the entry gate for eflornithine because down-regulation of AAT6 rendered both bloodstream and procyclic forms less sensitive toward the drug [13, 14, 61, 67] . Despite its intrinsic capacity to mediate uptake of amino acids in heterologous expression systems and the fact that AAT6 is a single copy gene, AAT6 is not essential for T. brucei survival, at least not under the in vitro conditions analyzed. This suggests that other transporters with overlapping substrate selectivities may compensate for loss of AAT6, emphasizing that drug resistance may emerge rapidly by deletion of a single transporter gene.
A heteromeric K + channel of Trypanosoma brucei is essential
One example for an essential plasma membrane transport system in T. brucei is a potassium channel that was originally identified through profile searches of the predicted T. brucei proteome against the conserved pore loop of cation channels [82] . The primary sequences of two of the hits, named TbK1 and TbK2, indicated that both are part of the family of putative Ca 2+ -activated potassium channels. The two gene products were shown to be essential for growth of bloodstream-form parasites, as RNAimediated down-regulation of the individual mRNAs led to growth arrest [82] . The genes were expressed in Xenopus oocytes and the functional properties of the encoded proteins investigated using electrophysiological techniques. Combined expression of TbK1 and TbK2 was required for efficient reconstitution of potassium ion transport in Xenopus oocytes, suggesting that these proteins assemble into a heteromeric ion channel [82] . The current mediated by this channel showed little time-and voltage dependence and displayed selectivity for potassium ions. The known potassium channel blocker barium inhibited this channel with an IC 50 of about 100 lM. RNAimediated down-regulation of either TbK1 or TbK2 mRNA eliminated a potassium conductance in the plasma membrane of T. brucei bloodstream forms [82] . It was concluded that TbK1 and TbK2 form a heteromeric potassium channel located in the plasma membrane and are involved in the modulation of its membrane potential, thus representing a novel drug target in T. brucei.
Using the X. laevis oocyte system for functional expression, we have started to screen libraries of substances that are known to interfere with growth of T. brucei for inhibition of TbK1/TbK2. Screening of the National Center for Advancing Translational Sciences Small Molecule Resource led to the identification of fluticasone propionate (FP) as an inhibitor of TbK1/TbK2-mediated channel function. The concentration-dependent inhibition was characterized by an IC 50 of 0.7 AE 0.5 lM (Fig. 3) . Substances with a similar pharmacophore are now being tested.
The myo-inositol transporter of Trypanosoma brucei is essential An additional example of an essential transporter in T. brucei is the proton-coupled myo-inositol transporter TbHMIT. myo-Inositol is a precursor for the synthesis of phosphatidylinositol (PI) and other inositol-containing membrane phospholipids, such as inositolphosphoryl ceramide and glycosylphosphatidylinositol (GPI), which can also serve to anchor cell surface proteins (reviewed in Ref. [83, 84] ). In addition, the polyalcohol myo-inositol is a component of a large group of signaling molecules involved in the regulation of cellular processes and is considered an important osmolyte in many eukaryotic cells (reviewed in Ref. [85] [86] [87] ). Although myo-inositol can be synthesized de novo in eukaryotes (reviewed in Ref. [85, 88] ), it can also be taken up from the environment via Na + -or H + -linked myo-inositol symporters (reviewed in Ref. [89] ). Many eukaryotic myo-inositol symporters have been characterized biochemically, however, only a few members have been found to be essential for cell viability (reviewed in Ref. [90, 91] ). In T. brucei procyclic and bloodstream forms, RNAi-mediated depletion of TbHMIT mRNA inhibited uptake of myo-inositol and blocked the synthesis of myo-inositol-containing phospholipids, but not the production of GPIs [92, 93] . Unexpectedly, TbHMIT was found to localize in both the plasma membrane and the Golgi [92, 93] . This, together with the previously reported dual localization of PI synthase in both the endoplasmic reticulum and the Golgi [94] , demonstrated that metabolism of exogenous and endogenous myo-inositol in T. brucei is strictly segregated, with the Golgi being the site of synthesis of bulk membrane PI utilizing exogenous myo-inositol, and the endoplasmic reticulum being the site of PI synthesis for GPI production utilizing de novo synthesized myo-inositol [92, 93, 95] (Fig. 4) . Such a model would imply that the synthesis of PI from CDP-diacylglycerol and myo-inositol, taken up into the Golgi via TbHMIT, occurs on the luminal side of the Golgi membrane ( Fig. 4 ; reviewed in [96] ).
Expression of TbHMIT in Xenopus oocytes revealed a remarkably high selectivity for myo-inositol. The inositol ring can only be modified at one position, for example, by removing a hydroxyl group at the 1-or 6-position or inversing the stereochemistry at a (single) hydroxyl group [93] . Interestingly, in contrast to other members of the GLUT/SLC2A family of transporters to which it belongs, TbHMIT shows no transport activity for monosaccharides [93] . TbHMIT thus represents a transporter that could be tested as a drug delivery system or as a drug target using substance libraries. , where it serves as precursor for bulk PI synthesis. In contrast, PI needed for GPI synthesis is synthesized from 1-D-myo-inositol-3-phosphate in the endoplasmic reticulum from where it is translocated to the cytosolic leaflet of the ER membrane. After conversion to Nacetylglucosamine-PI (GlcNAc-PI) followed by deacetylation, glucosamine-PI (GlcN-PI) is translocated back to the luminal side of the ER membrane where it serves as precursor for the formation of free GPIs and GPI-anchored proteins. Not all reaction intermediates are shown. The transporters or scramblases involved in GPI precursor transport across the ER membrane (in orange color) have not been identified on a molecular level. Adapted from [96] .
Conclusions
Transporters are increasingly being recognized as key players in cell physiology and determinants of drug susceptibility. This is particularly the case for parasites, which-by definition-rely on import of nutrients and ions from their hosts and therefore require specific transporters and channels. However, in spite of the fact that a large proportion of the known drugs interferes with transporters of the plasma membrane, the chemotherapeutic armory against trypanosomatids presently does not contain inhibitors of nutrient transporters or ion channels. Thus, the pharmacological potential of transporters for parasite chemotherapy remains to be exploited.
The African trypanosomes T. brucei, thanks to the established reverse genetic technologies, provide a convenient system to experimentally validate transporters as potential drug targets or drug delivery devices. One of the challenges with T. brucei is the high degree of redundancy of nutrient transporter genes, which is illustrated by the expansion of gene families for the transport of organic nutrients such as hexoses, purines, or amino acids, toward large numbers of paralogs that occur as polycistronic transcription units. The genetic redundancy of nutrient transporters in T. brucei exacerbates the fact that individual transporters seem to have a comparably low likelihood for being essential. Thus, it appears to be particularly difficult to identify genes encoding essential transporters in T. brucei. Yet, essentiality is a prerequisite if the trypanosome is to be killed by inhibition of a transporter. Also other chemotherapeutic attacks involving transporters, such as drug delivery or hyperactivation, are more effective if the targeted transporter is essential. Otherwise, loss-offunction mutations would provide an easy means for the parasite to become drug resistant. In this review, we show how the systematic characterization of T. brucei genes in expression systems and in the trypanosomes themselves has identified the first plasma membrane transporters of T. brucei that are essential for the survival of T. brucei bloodstream forms in culture. These are the heteromeric potassium channel TbK1/TbK2 and the proton-coupled myo-inositol transporter TbHMIT. In addition, the arginine, lysine, and ornithine permeases are also required for normal growth, yet, transport of these amino acids cannot be ablated by knocking out single genes. We hope that such potential targets serve as starting points toward exploiting nutrient transporters and ion transporters for trypanosomatid chemotherapy.
